BioHealx® Anal Fistula Device Post Market Surveillance Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSignum Surgical USA Inc.

About this trial

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 - 75 years

Presence of Single Continuous Anal Fistula presenting for initial curative surgery

Failed or Recurrent Anal Fistula Closure

Minimum of 6-weeks of draining seton placed prior to procedure.

Disqualifiers

Fistula tract shorter than 2cm

Complex fistula tract (branching)

Body Mass Index > 35

Known uncontrolled diabetes or other systemic condition associated with impaired healing

Trial population

Patients presenting for treatment of mature, cryptogenic, transsphincteric, non-branching fistulas in ano via tissue apposition.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • BioHealx

    Device

    Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: BioHealx1 intervention

Trial outcomes

Primary outcomes

1

Successful Closure Repair

Successful closure repair of the anal fistula as determined by complete healing, i.e., internal and external opening closed (no evidence of an external opening present) without drainage

Time frame
12 Months
2

Non-Recurrence Incidence

Non-recurrence incidence determined by continued closure of the external fistula opening.

Time frame
24 and 36 Months

Secondary outcomes

1

Fecal Incontinence Quality of Life

Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life.

Time frame
6 Months, 9 Months, 12 Months, 24 Months, 36 Months
2

Fecal Incontinence Severity Index (FISI)

Fecal Incontinence Severity Index (FISI) at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.

Time frame
6 Month, 9 Month, 12 Month, 24 Month, 36 Month
3

Health Related Quality of Life

SF-36 Quality of life data will be collected (baseline visit and from 6-month and at each subsequent follow-up visit). Short Form 36 (SF-36) is a generic self-reported outcome measure that quantifies the quality of life in relation to health status. It is a 36-item valid and reliable evaluation with eight areas covering physical functioning, role limitations brought on by physical issues, bodily pain, general health perceptions, vitality, social functioning, role limitations brought on by emotional issues, and perceived mental health. The SF-36 also contains a single question called "health transition" that measures how respondents feel their over health status has changed over the course of a year. The scores range from 0-100 (the worst possible to the most possible)

Time frame
6 Months, 9 Months, 12 Months, 24 Months, 36 Months
4

Pain Score

Wong-Baker FACES Pain scores will be recorded at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The FACES Pain Scale ranges from 0 (no pain) to 10 (the worst pain).

Time frame
6 Months, 9 Months, 12 Months, 24 Months, 36 Months

Other outcomes

1

Device and Procedure Related Adverse Events

Measurement of device and/or procedure related adverse events will be recorded.

Time frame
6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
2

Adverse Event Comparison

Measurement of, incidence, severity and persistence of device and/or procedure related adverse events will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and relevant comparator devices (e.g. cutting seton) and procedures (e.g., LIFT).

Time frame
6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
3

Occurrence of Fecal Incontinence

Fecal continence will be measured through combination of the patient reported Fecal Incontinence Quality of Life questionnaire (FIQL) and the Fecal Incontinence Severity Index questionnaire (FISI) scores at baseline and subsequent periods. Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life. The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.

Time frame
Baseline, 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months
4

Rescue Analgesic and Therapeutic Antibiotic Comparison

Rescue analgesic and therapeutic antibiotic use will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and other relevant fistula treatments.

Time frame
6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.